Stressed out: The skeletal muscle ryanodine receptor as a target of stress

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 445-453

  Bellinger, Andrew M ^a   Mongillo, Marco ^a   Marks, Andrew R ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; RAPAMYCIN; RYANODINE RECEPTOR 1; TACROLIMUS;

GENE MUTATION; GENETIC CODE; HEART FAILURE; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE STRESS; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; STRESS;

ANIMALS; CALCIUM; EXERCISE TOLERANCE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE FATIGUE; MUSCLE, SKELETAL; MUSCULAR DISEASES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; STRESS, MECHANICAL;

EID: 38849094092     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34006     Document Type: Review

References (125)

1. Tanabe, T., Beam, K.G., Adams, B.A., Niidome, T., and Numa, S. 1990. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature. 346:567-569.
2. Fill, M., and Copello, J.A. 2002. Ryanodine receptor calcium release channels. Physiol. Rev. 82:893-922.
3. Gonzalez-Serratos, H., Valle-Aguilera, R., Lathrop, D.A., and Garcia, M.C. 1982. Slow inward calcium currents have no obvious role in muscle excitation-contraction coupling. Nature. 298:292-294.
4. Rios, E., and Brum, G. 1987. Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. Nature. 325:717-720.
5. Catterall, W.A. 1991. Excitation-contraction coupling in vertebrate skeletal muscle: a tale of two calcium channels. Cell. 64:871-874.
6. Ebashi, S. 1991. Excitation-contraction coupling and the mechanism of muscle contraction. Annu. Rev. Physiol. 53:1-16.
7. Reiken, S., et al. 2003. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J. Cell Biol. 160:919-928.
8. Lunde, P.K., et al. 2001. Contraction and intracellular Ca(2+) handling in isolated skeletal muscle of rats with congestive heart failure. Circ. Res. 88:1299-1305.
9. Westerblad, H., and Allen, D.G. 1991. Changes of myoplasmic calcium concentration during fatigue in single mouse muscle fibers. J. Gen. Physiol. 98:615-635.
10. Takeshima, H., et al. 1989. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature. 339:439-445.
11. Marks, A.R., et al. 1989. Molecular cloning and characterization of the ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum. Proc. Natl Acad. Sci. U. S. A. 86:8683-8687.
12. Zalk, R., Lehnart, S.E., and Marks, A.R. 2007. Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76:367-385.
13. Marx, S.O., Ondrias, K., and Marks, A.R. 1998. Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors). Science. 281:818-821.
14. Stange, M., Xu, L., Balshaw, D., Yamaguchi, N., and Meissner, G. 2003. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J. Biol. Chem. 278:51693-51702.
15. Eu, J.P., Xu, L., Stamler, J.S., and Meissner, G. 1999. Regulation of ryanodine receptors by reactive nitrogen species. Biochem. Pharmacol. 57:1079-1084.
16. Sun, J., Xin, C., Eu, J.P., Stamler, J.S., and Meissner, G. 2001. Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc. Natl. Acad. Sci. U. S. A. 98:11158-11162.
17. Aracena, P., Tang, W., Hamilton, S., and Hidalgo, C. 2005. Effects of S-glutathionylation and S-nitrosylation on calmodulin binding to triads and FKBP12 binding to type 1 calcium release channels. Antioxid. Redox Signal. 7:870-881.
18. Aghdasi, B., Zhang, J.Z., Wu, Y., Reid, M.B., and Hamilton, S.L. 1997. Multiple classes of sulfhydryls modulate the skeletal muscle Ca2+ release channel. J. Biol. Chem. 272:3739-3748.
19. Aracena, P., Sanchez, G., Donoso, P., Hamilton, S.L., and Hidalgo, C. 2003. S-glutathionylation decreases Mg2+ inhibition and S-nitrosylation enhances Ca2+ activation of RyR1 channels. J. Biol. Chem. 278:42927-42935.
20. Favero, T.G., Zable, A.C., Bowman, M.B., Thompson, A., and Abramson, J.J. 1995. Metabolic end products inhibit sarcoplasmic reticulum Ca2+ release and [3H]ryanodine binding. J. Appl. Physiol. 78:1665-1672.
21. Aghdasi, B., Reid, M.B., and Hamilton, S.L. 1997. Nitric oxide protects the skeletal muscle Ca2+ release channel from oxidation induced activation. J. Biol. Chem. 272:25462-25467.
22. Stamler, J.S., and Meissner, G. 2001. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 81:209-237.
23. Tripathy, A., Xu, L., Mann, G., and Meissner, G. 1995. Calmodulin activation and inhibition of skeletal muscle Ca2+ release channel (ryanodine receptor). Biophys. J. 69:106-119.
24. Fluck, M. 2006. Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli. J. Exp. Biol. 209:2239-2248.
25. Fitts, R.H. 1994. Cellular mechanisms of muscle fatigue. Physiol. Rev. 74:49-94.
26. Olafsson, E., Jones, H.R.J., Guay, A.T., and Thomas, C.B. 1994. Myopathy of endogenous Cushing's syndrome: a review of the clinical and electromyographic features in 8 patients. Muscle Nerve. 17:692-693.
27. Webster, C., Silberstein, L., Hays, A.P., and Blau, H.M. 1988. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 52:503-513.
28. Schoser, B.G.H., and Pongratz, D. 2006. Extraocular mitochondrial myopathies and their differential diagnoses. Strabismus. 14:107-113.
29. MacLennan, D.H., and Phillips, M.S. 1992. Malignant hyperthermia. Science. 256:789-794.
30. Robert, V., et al. 2001. Alteration in calcium handling at the subcellular level in mdx myotubes. J. Biol. Chem. 276:4647-4651.
31. Zhou, H., et al. 2007. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain. 130:2024-2036.
32. Mickelson, J.R., and Louis, C.F. 1996. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol. Rev. 76:537-592.
33. Priori, S.G., and Napolitano, C. 2005. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. J. Clin. Invest. 115:2033-2038.
34. Mickelson, J.R., et al. 1988. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 263:9310-9315.
35. Richter, M., Schleithoff, L., Deufel, T., Lehmann-Horn, F., and Herrmann-Frank, A. 1997. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle. J. Biol. Chem. 272:5256-5260.
36. Censier, K., Urwyler, A., Zorzato, F., and Treves, S. 1998. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg-163Cys mutated ryanodine receptors. J. Clin. Invest. 101:1233-1242.
37. Denborough, M. 1998. Malignant hyperthermia. Lancet. 352:1131-1136.
38. Tobin, J.R., Jason, D.R., Challa, V.R., Nelson, T.E., and Sambuughin, N. 2001. Malignant hyperthermia and apparent heat stroke. JAMA. 286:168-169.
39. Stewart, S.L., Hogan, K., Rosenberg, H., and Fletcher, J.E. 2001. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin. Genet. 59:178-184.
40. Krause, T., Gerbershagen, M.U., Fiege, M., Weisshorn, R., and Wappler, F. 2004. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 59:364-373.
41. Cabello, A., and Ricoy-Campo, J.R. 2003. Congenital myopathies. Rev. Neurol. 37:779-786.
42. Quane, K.A., et al. 1993. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat. Genet. 5:51-55.
43. Zhang, Y., et al. 1993. A mutation in the human ryanodine receptor gene associated with central core disease. Nat. Genet. 5:46-50.
44. Tilgen, N., et al. 2001. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum. Mol. Genet. 10:2879-2887.
45. Tong, J., McCarthy, T.V., and MacLennan, D.H. 1999. Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. J. Biol. Chem. 274:693-702.
46. Gommans, I.M., Vlak, M.H., de Haan, A., and van Engelen, B.G. 2002. Calcium regulation and muscle disease. J. Muscle Res. Cell Motil. 23:59-63.
47. Wu, S., et al. 2006. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain. 129:1470-1480.
48. Avila, G., O'Connell, K.M., and Dirksen, R.T. 2003. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J. Gen. Physiol. 121:277-286.
49. Dirksen, R.T., and Avila, G. 2004. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys. J. 87:3193-3204.
50. Mathews, K.D., and Moore, S.A. 2004. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces? Arch. Neurol. 61:27-29.
51. Matsumura, K., Ervasti, J.M., Ohlendieck, K., Kahl, S.D., and Campbell, K.P. 1992. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature. 360:588-591.
52. Deconinck, N., and Dan, B. 2007. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36:1-7.
53. Plant, D.R., and Lynch, G.S. 2003. Depolarization-induced contraction and SR function in mechanically skinned muscle fibers from dystrophic mdx mice. Am. J. Physiol. Cell Physiol. 285:C522-C528.
54. Woods, C.E., Novo, D., DiFranco, M., and Vergara, J.L. 2004. The action potential-evoked sarcoplasmic reticulum calcium release is impaired in mdx mouse muscle fibres. J. Physiol. 557:59-75.
55. Woods, C.E., Novo, D., DiFranco, M., Capote, J., and Vergara, J.L. 2005. Propagation in the transverse tubular system and voltage dependence of calcium release in normal and mdx mouse muscle fibres. J. Physiol. 568:867-880.
56. Eberstein, A., and Sandow, A. 1963. Fatigue mechanisms in muscle fibers. E. Gutman, and P. Hink, editors. In Effect of use and disuse on neuromuscular functions. Elsevier. Amsterdam, The Netherlands. 515-526.
57. Allen, D., Lee, J., and Westerblad, H. 1989. Intracellular calcium and tension during fatigue in isolated single muscle fibres from Xenopus laevis. J. Physiol. (Lond.). 415:433-458.
58. Westerblad, H., Lee, J.A., Lamb, A.G., Bolsover, S.R., and Allen, D.G. 1990. Spatial gradients of intracellular calcium in skeletal muscle during fatigue. Pflugers Arch. 415:734-740.
59. Gyorke, S. 1993. Effects of repeated tetanic stimulation on excitation-contraction coupling in cut muscle fibers of the frog. J. Physiol. 464:699-710.
60. Baker, A.J., Longuemare, M.C., Brandes, R., and Weiner, M.W. 1993. Intracellular tetanic calcium signals are reduced in fatigue of whole skeletal muscle. Am. J. Physiol. Cell Physiol. 264:C577-C582.
61. Favero, T.G., Pessah, I.N., and Klug, G.A. 1993. Prolonged exercise reduces Ca2+ release in rat skeletal muscle sarcoplasmic reticulum. Pflugers Arch. 422:472-475.
62. Allen, D.G., and Westerblad, H. 2001. Role of phosphate and calcium stores in muscle fatigue. J. Physiol. 536:657-665.
63. Westerblad, H., Duty, S., and Allen, D.G. 1993. Intracellular calcium concentration during low-frequency fatigue in isolated single fibers of mouse skeletal muscle. J. Appl. Physiol. 75:382-388.
64. Scherer, N.M., and Deamer, D.W. 1986. Oxidative stress impairs the function of sarcoplasmic reticulum by oxidation of sulfhydryl groups in the Ca2+-ATPase. Arch. Biochem. Biophys. 246:589-601.
65. Chin, E.R., and Allen, D.G. 1996. The role of elevations in intracellular [Ca2+] in the development of low frequency fatigue in mouse single muscle fibres. J. Physiol. 491:813-824.
66. Lamb, G.D., Junankar, P.R., and Stephenson, D.G. 1995. Raised intracellular [Ca2+] abolishes excitation-contraction coupling in skeletal muscle fibres of rat and toad. J. Physiol. 489:349-362.
67. Edwards, R.H., Hill, D.K., Jones, D., and Merton, P.A. 1977. Fatigue of long duration in human skeletal muscle after exercise. J. Physiol. 272:769-778.
68. Westerblad, H., Bruton, J.D., Allen, D.G., and Lannergren, J. 2000. Functional significance of Ca2+ in long-lasting fatigue of skeletal muscle. Eur. J. Appl. Physiol. 83:166-174.
69. Fryer, M.W., Owen, V.J., Lamb, G.D., and Stephenson, D.G. 1995. Effects of creatine phosphate and P(i) on Ca2+ movements and tension development in rat skinned skeletal muscle fibres. J. Physiol. 482:123-140.
70. Westerblad, H., and Allen, D.G. 1996. The effects of intracellular injections of phosphate on intracellular calcium and force in single fibres of mouse skeletal muscle. Pflugers Arch. 431:964-970.
71. Wang, X., et al. 2005. Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle. Nat. Cell Biol. 7:525-530.
72. Brillantes, A.B., et al. 1994. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 77:513-523.
73. Lamb, G.D., and Stephenson, D.G. 1996. Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. J. Physiol. 494:569-576.
74. Avila, G., Lee, E.H., Perez, C.F., Allen, P.D., and Dirksen, R.T. 2003. FKBP12 binding to RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes. J. Biol. Chem. 278:22600-22608.
75. Shou, W., et al. 1998. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature. 391:489-492.
76. Tang, W., et al. 2004. Altered excitation-contraction coupling with skeletal muscle specific FKBP12 deficiency. FASEB J. 18:1597-1599.
77. Favero, T.G. 1999. Sarcoplasmic reticulum Ca2+ release and muscle fatigue. J. Appl. Physiol. 87:471-483.
78. Rall, J. 1982. Energetics of Ca2+ cycling during skeletal muscle contraction. Fed. Proc. 41:155-160.
79. Wahr, P.A., and Rall, J.A. 1997. Role of calcium and cross bridges in determining rate of force development in frog muscle fibers. Am. J. Physiol. Cell Physiol. 272:C1664-C1671.
80. Westerblad, H., and Allen, D.G. 2002. Recent advances in the understanding of skeletal muscle fatigue. Curr. Opin. Rheumatol. 14:648-652.
81. Meyer, M., et al. 1998. Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations. J. Mol. Cell. Cardiol. 30:1459-1470.
82. Gissel, H. 2005. The role of Ca2+ in muscle cell damage. Ann. N. Y. Acad. Sci. 1066:166-180.
83. Tidball, J.G., and Spencer, M.J. 2000. Calpains and muscular dystrophies. Int. J. Biochem. Cell Biol. 32:1-5.
84. Spencer, M.J., and Mellgren, R.L. 2002. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum. Mol. Genet. 11:2645-2655.
85. Minotti, J.R., et al. 1991. Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance. J. Clin. Invest. 88:2077-2082.
86. Sullivan, M.J., and Hawthorne, M.H. 1995. Exercise intolerance in patients with chronic heart failure. Prog. Cardiovasc. Dis. 38:1-22.
87. Minotti, J.R., et al. 1990. Skeletal muscle response to exercise training in congestive heart failure. J. Clin. Invest. 86:751-758.
88. Perreault, C.L., et al. 1993. Alterations in contractility and intracellular Ca2+ transients in isolated bundles of skeletal muscle fibers from rats with chronic heart failure. Circ. Res. 73:405-412.
89. Ward, C.W., et al. 2003. Defects in ryanodine receptor calcium release in skeletal muscle from postmyocardial infarct rats. FASEB J. 17:1517-1519.
90. Lunde, P.K., Verburg, E., Eriksen, M., and Sejersted, O.M. 2002. Contractile properties of in situ perfused skeletal muscles from rats with congestive heart failure. J. Physiol. (Lond.). 540:571-580.
91. Szigeti, G.P., et al. 2007. Alterations in the calcium homeostasis of skeletal muscle from postmyocardial infarcted rats. Pflugers Arch. 455:541-553.
92. Lefkowitz, R.J., Rockman, H.A., and Koch, W.J. 2000. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 101:1634-1637.
93. Fozzard, H.A. 1977. Heart: excitation-contraction coupling. Annu. Rev. Physiol. 39:201-220.
94. Viguerie, N., et al. 2004. In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle. J. Clin. Endocrinol. Metab. 89:2000-2014.
95. Saltin, B. 1988. Capacity of blood flow delivery to exercising skeletal muscle in humans. Am. J. Cardiol. 62:30E-35E.
96. Tan, L.B., Burniston, J.G., Clark, W.A., Ng, Y., and Goldspink, D.F. 2003. Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity Induced by sympathomimetic agents: toward a new bioassay for beta-blockers. J. Cardiovasc. Pharmacol. 41:518-525.
97. Wehrens, X.H., et al. 2005. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc. Natl. Acad. Sci. U. S. A. 102:9607-9612.
98. Supinski, G., and Callahan, L.A. 2007. Free radical mediated skeletal muscle dysfunction in inflammatory conditions. J. Appl. Physiol. 102:2056-2063.
99. Riede, U.N., Förstermann, U., and Drexler, H. 1998. Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 32:964-969.
100. Shah, K.R., Ganguly, P.K., Netticadan, T., Arneja, A.S., and Dhalla, N.S. 2004. Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade. Can. J. Physiol. Pharmacol. 82:438-447.
101. Tsutsui, H., et al. 2001. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation. 104:134-136.
102. Dalla, L.L., et al. 2005. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. J. Mol. Cell. Cardiol. 38:803-807.
103. Isaeva, E.V., Shkryl, V.M., and Shirokova, N. 2005. Mitochondrial redox state and Ca2+ sparks in permeabilized mammalian skeletal muscle. J. Physiol. 565:855-872.
104. Lunde, P.K., Verburg, E., Vollestad, N.K., and Sejersted, O.M. 1998. Skeletal muscle fatigue in normal subjects and heart failure patients. Is there a common mechanism? Acta. Physiol. Scand. 162:215-228.
105. Hill, A.V., and Kupalov, P. 1929. Anaerobic and aerobic activity in isolated muscle. Proc. R. Soc. Lond. B Biol. Sci. 105:313-322.
106. Andrews, M.A., Godt, R.E., and Nosek, T.M. 1996. Influence of physiological L(+)-lactate concentrations on contractility of skinned striated muscle fibers of rabbit. J. Appl. Physiol. 80:2060-2065.
107. Dutka, T.L., and Lamb, G.D. 2000. Effect of lactate on depolarization-induced Ca2+ release in mechanically skinned skeletal muscle fibers. Am. J. Physiol. Cell Physiol. 278:C517-C525.
108. Pedersen, T.H., Nielsen, O.B., Lamb, G.D., and Stephenson, D.G. 2004. Intracellular acidosis enhances the excitability of working muscle. Science. 305:1144-1147.
109. Gomez, A.M., et al. 1997. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 276:800-806.
110. Belcastro, A.N. 1993. Skeletal muscle calcium-activated neutral protease (calpain) with exercise. J. Appl. Physiol. 74:1381-1386.
111. Charge, S.B., and Rudnicki, M.A. 2004. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 84:209-238.
112. Cossu, G., and Sampaolesi, M. 2004. New therapies for muscular dystrophy: cautious optimism. Trends Mol. Med. 10:516-520.
113. Sandri, M., et al. 2006. PGC-1{alpha} protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. U. S. A. 103:16260-16265.
114. Jurkat-Rott, K., and Lehmann-Horn, F. 2005. Muscle channelopathies and critical points in functional and genetic studies. J. Clin. Invest. 115:2000-2009.
115. Du, J., et al. 2004. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest. 113:115-123.
116. Zuo, L., Christofi, F.L., Wright, V.P., Bao, S., and Clanton, T.L. 2004. Lipoxygenase-dependent superoxide release in skeletal muscle. J. Appl. Physiol. 97:661-668.
117. Rudolf, R., Mongillo, M., Magalhaes, P.J., and Pozzan, T. 2004. In vivo monitoring of Ca2+ uptake into mitochondria of mouse skeletal muscle during contraction. J. Cell Biol. 166:527-536.
118. Allen, D.G., Whitehead, N.P., and Yeung, E.W. 2005. Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: role of ionic changes. J. Physiol. (Lond.). 567:723-735.
119. Doran, P., Gannon, J., O'Connell, K., and Ohlendieck, K. 2007. Aging skeletal muscle shows a drastic increase in the small heat shock proteins alphaB-crystallin/HspB5 and cvHsp/HspB7. Eur. J. Cell. Biol. 86:629-640.
120. Brooksbank, R.L., Badenhorst, M.E., Isaacs, H., and Savage, N. 1998. Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture. Anesthesiology. 89:693-698.
121. Ahern, G.P., Junankar, P.R., and Dulhunty, A.F. 1997. Subconductance states in single-channel activity of skeletal muscle ryanodine receptors after removal of FKBP12. Biophys. J. 72:146-162.
122. Yeung, E.W., et al. 2005. Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse. J. Physiol. 562:367-380.
123. Peter, A.K., Miller, G., and Crosbie, R.H. 2007. Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice. J. Cell Sci. 120:996-1008.
124. Michele, D.E., et al. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 418:417-421.
125. Bansal, D., et al. 2003. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 423:168-172.